Vincerx Pharma, Inc. (VINC) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Vincerx Pharma, Inc. (VINC) trades at $0.013. Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies. Their lead product candidate, VIP152, targets advanced cancers, while other preclinical programs address solid tumors and hematologic malignancies. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for VINC: VINC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VINC against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on VINC.
How is this calculated? →Vincerx Pharma, Inc. (VINC) Healthcare & Pipeline Overview
Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical firm specializing in cancer therapies, including VIP152, a CDK9 inhibitor. With a focus on unmet medical needs, the company develops small molecule drug conjugates and oral PTEFb/CDK9 inhibitors, positioning itself within the competitive biotechnology landscape.
What Is the Investment Thesis for VINC?
Vincerx Pharma presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's valuation is currently dependent on the successful development and commercialization of its pipeline assets, particularly VIP152. Key value drivers include positive clinical trial results for VIP152 and the advancement of preclinical candidates into clinical stages. The company's negative profit margin of -1951.0% highlights its reliance on future revenue streams. Growth catalysts include potential partnerships, regulatory approvals, and successful clinical trial outcomes. Potential risks include clinical trial failures, regulatory hurdles, and the need for additional capital to fund ongoing research and development. The company's beta of 1.55 indicates higher volatility compared to the market.
Based on FMP financials and quantitative analysis
VINC Key Highlights
Vincerx Pharma operates with a small team of 12 employees, reflecting its current stage as a clinical-stage biopharmaceutical company.
- The company's lead product candidate, VIP152, is a cyclin-dependent kinase-9 inhibitor targeting advanced cancer, representing a key potential value driver.
- Vincerx Pharma's pipeline includes preclinical-stage product candidates like VIP217 and VIP236, indicating a focus on future growth and diversification.
- The company's gross margin of 50.0% suggests potential for profitability upon successful commercialization of its products.
- Vincerx Pharma's market capitalization is $0.00B, reflecting its early stage and the speculative nature of its valuation.
Who Are VINC's Competitors?
VINC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DRMA Dermata Therapeutics, Inc. | $1.38 | -6.12% | — | |
| PIII P3 Health Partners Inc. | $10.27 | -4.64% | $33.6M | — |
| PPBT Purple Biotech Ltd. | $1.58 | -0.63% | 43 | |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VINC's Key Strengths?
Innovative pipeline of cancer therapies.
- Lead product candidate targeting a validated cancer target (CDK9).
- Experienced management team.
- Proprietary technology platform.
What Are VINC's Weaknesses?
Limited financial resources.
- Dependence on the success of a few key product candidates.
- Small team size.
- Lack of commercialized products.
What Could Drive VINC Stock Higher?
Clinical trial results for VIP152.
- Advancement of VIP217 into clinical trials.
- Announcement of strategic partnerships or collaborations.
- Regulatory interactions and potential approvals.
What Are the Key Risks for VINC?
Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for VIP152 or other product candidates.
- Regulatory delays or rejections.
- Competition from other biotechnology companies.
- Need for additional capital to fund research and development.
- Patent challenges or expirations.
What Are the Growth Opportunities for VINC?
- Expansion of VIP152 Clinical Trials: Vincerx has the opportunity to expand the clinical trials for VIP152 to include additional cancer types and patient populations. This could significantly increase the potential market size for VIP152, which is currently focused on advanced cancers. Successful trial outcomes and subsequent regulatory approvals could drive substantial revenue growth. The timeline for expansion depends on ongoing trial results and regulatory interactions.
- Advancement of Preclinical Pipeline: Vincerx can advance its preclinical pipeline, including VIP217, VIP236, VIP943, and VIP924, into clinical development. This would diversify the company's product portfolio and reduce its reliance on VIP152. Each candidate targets different aspects of cancer treatment, potentially opening up new market segments. The timeline for this depends on preclinical study results and securing funding for clinical trials.
- Strategic Partnerships and Collaborations: Vincerx can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its product candidates. This could provide access to additional funding, expertise, and resources. Partnerships could also expand the company's geographic reach and market access. The timing and success of partnerships depend on the attractiveness of Vincerx's pipeline and the strategic priorities of potential partners.
- Targeting Specific Cancer Subtypes: Vincerx has the opportunity to focus its research and development efforts on specific cancer subtypes with high unmet medical needs. This targeted approach could increase the likelihood of clinical success and regulatory approval. Identifying and validating specific biomarkers for patient selection could further enhance the effectiveness of its therapies. The timeline for this depends on ongoing research and the identification of suitable cancer subtypes.
- Exploring Combination Therapies: Vincerx can explore the potential of combining its product candidates with existing cancer therapies to improve treatment outcomes. Combination therapies can often enhance efficacy and overcome resistance mechanisms. This approach could create new market opportunities and extend the lifespan of existing therapies. The timeline for this depends on preclinical and clinical studies to evaluate the safety and efficacy of combination regimens.
What Are VINC's Competitive Advantages?
- Proprietary drug candidates with unique mechanisms of action.
- Patent protection for its therapies.
- Expertise in CDK9 inhibition and small molecule drug conjugates.
- Focus on specific cancer subtypes with high unmet needs.
What Does VINC Do?
Founded in 2019 and headquartered in Palo Alto, California, Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company dedicated to researching and developing innovative therapies for cancer treatment. The company's mission centers on addressing unmet medical needs within the oncology space. Vincerx's lead product candidate, VIP152, is a cyclin-dependent kinase-9 (CDK9) inhibitor designed for patients battling advanced cancer. In addition to VIP152, Vincerx Pharma is advancing a pipeline of preclinical-stage product candidates, including VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate targeting solid tumors; and VIP943 and VIP924, specifically developed for the treatment of hematologic malignancies. Vincerx Pharma operates primarily in the United States, focusing its research and development efforts on creating targeted cancer therapies. The company aims to improve patient outcomes by developing novel treatments that address the limitations of existing cancer therapies. Vincerx is committed to advancing its pipeline through clinical trials and regulatory approvals, with the goal of bringing innovative cancer treatments to market.
What Products and Services Does VINC Offer?
- Researches and develops therapies for cancer treatment.
- Focuses on addressing unmet medical needs in oncology.
- Develops cyclin-dependent kinase-9 (CDK9) inhibitors.
- Creates small molecule drug conjugates for solid tumors.
- Develops treatments for hematologic malignancies.
- Conducts preclinical and clinical studies to evaluate drug candidates.
- Seeks regulatory approvals for its therapies.
How Does VINC Make Money?
- Develops and patents novel cancer therapies.
- Conducts preclinical and clinical research to validate drug candidates.
- Out-licenses or partners with larger pharmaceutical companies for commercialization.
- Generates revenue through licensing agreements and potential product sales.
What Industry Does VINC Operate In?
Vincerx Pharma operates within the competitive biotechnology industry, characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful therapies. The industry is driven by innovation and the constant pursuit of novel treatments for unmet medical needs. Vincerx competes with other biotechnology companies, including ACON, DRMA, FOXO, PIII, and PPBT, all vying for market share in the oncology space. The biotechnology industry is experiencing growth, driven by advancements in genomics, personalized medicine, and targeted therapies. Vincerx aims to capitalize on these trends by developing innovative cancer treatments.
Who Are VINC's Key Customers?
- Patients with advanced cancer.
- Oncologists and hematologists.
- Hospitals and cancer treatment centers.
- Pharmaceutical companies (potential partners).
Company Profile
Vincerx Pharma, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Palo Alto, US. The company is led by CEO Raquel E. Izumi. VINC has traded publicly since 2020.
Financial Health
Vincerx Pharma, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Forward Outlook
Wall Street analysts project Vincerx Pharma, Inc. revenue of about $220K for fiscal 2026, with EPS near $-11.40.
Insider Activity
The most recent 10 insider filings for Vincerx Pharma, Inc. break down as 3 sales and 7 purchases. On net that is roughly 382K shares acquired (about $72K) — insiders putting money in tends to read as conviction.
VINC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Vincerx's pipeline, indicating potential positive developments ahead.
- Community sentiment has turned increasingly optimistic as recent clinical trials show promising results, boosting investor interest.
- Social media discussions highlight Vincerx's innovative approach to targeted therapies, attracting attention from biotech enthusiasts.
- Analysts are noting a shift in market perception, with more investors recognizing the long-term potential of Vincerx's unique drug candidates.
Bear Case
- Concerns remain about the competitive landscape, with several established players advancing similar treatments, which could impact market share.
- Recent quarterly reports have raised questions about cash burn rates, leading to worries about sustainability in the current market environment.
- Community sentiment has shown some volatility, with bearish discussions emerging around potential delays in regulatory approvals.
- Market perception has been cautious, with some investors fearing that the excitement may not translate into tangible results in the near term.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
VINC Latest News
No recent news available for VINC.
VINC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VINC.
Price Targets
Wall Street price target analysis for VINC.
VINC MoonshotScore
What does this score mean?
The MoonshotScore rates VINC 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Raquel E. Izumi
Unknown
Raquel E. Izumi's background information is not available in the provided data. Without additional information, it's impossible to detail her career history, education, previous roles, or credentials. Further research would be needed to provide a comprehensive profile.
Track Record: Raquel E. Izumi's track record is not available in the provided data. There is no information about her key achievements, strategic decisions, or company milestones under her leadership. Further research would be needed to provide a comprehensive assessment of her performance.
VINC OTC Market Information
VINC trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
Common Questions About VINC (Healthcare)
What does Vincerx Pharma, Inc. do?
Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company focused on researching and developing innovative therapies for the treatment of cancer. Their lead product candidate, VIP152, is a cyclin-dependent kinase-9 (CDK9) inhibitor designed to treat advanced cancers.
What do analysts say about VINC stock?
Analyst consensus on Vincerx Pharma, Inc. (VINC) is currently unavailable due to the company's early stage and limited market capitalization. Key valuation metrics are difficult to assess given the company's negative profit margin and reliance on future revenue streams from its pipeline assets.
What are the main risks for VINC?
The main risks for Vincerx Pharma, Inc. include the potential for clinical trial failures, regulatory hurdles, and competition from other biotechnology companies. The company's dependence on the successful development and commercialization of its pipeline assets, particularly VIP152, poses a significant risk. Additionally, Vincerx Pharma requires additional capital to fund its ongoing research and development activities, which could dilute existing shareholders.
What are the key factors to evaluate for VINC?
Evaluate VINC on fundamentals, analyst consensus, and risk factors. Vincerx Pharma presents a high-risk, high-reward investment opportunity within the biotechnology sector. Not financial advice.
How frequently does VINC data refresh on this page?
VINC's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven VINC's recent stock price performance?
Vincerx Pharma, Inc. (VINC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative pipeline of cancer therapies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VINC overvalued or undervalued right now?
Vincerx Pharma, Inc. (VINC) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research VINC before investing?
Before investing in Vincerx Pharma, Inc. (VINC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-16.
- AI analysis pending for VINC.
- CEO background and track record are limited due to data availability.